title: Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
abstract: BACKGROUND
  Cytomegalovirus (CMV) disease represents an important cause of morbidity in renal transplant recipients. We report our preliminary evaluation of the efficacy and security of preemptive therapy to manage renal transplant recipients with evidence of active CMV replication.
  
  
  METHODS
  Preemptive therapy with gancyclovir and/or valgancyclovir (VGCV) was recently substituted for CMV antiviral prophylaxis at our institution. Between May 2006 and December 2007, all patients undergoing renal transplantation were included in a CMV infection surveillance program. Blood samples to determine CMV viral load were obtained weekly during the first 4 months. Asymptomatic patients, with a viral load determined using polymerase chain reaction (PCR) with CMV DNA >100,000 copies/mL, were treated with VGCV for 3 months or until resolution of viral replication. Until April 2006, patients undergoing renal transplantation received CMV prophylaxis with oral acyclovir and pp65 antigenemia was the test for CMV infection surveillance. The group on preemptive therapy was compared with a historical group on prophylaxis therapy: 100 renal patients who underwent transplantation between April 2004 and 2006.
  
  
  RESULTS
  Among 96 recipients, quantitative determination of viral DNA in blood was elevated in 14 asymptomatic patients, who were treated with oral VGCV for 3 months. The patients were followed up for a median time of 13.3 months. None of the 14 patients who received VGCV developed CMV disease.
  
  
  CONCLUSIONS
  VGCV administered as preemptive therapy was safe and efficacious to prevent CMV disease.
authors.affiliation: Renal Unit, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Paudice
authors.forename: A
authors.initials: A
authors.lastname: Mehmetaj
authors.forename: M
authors.initials: M
authors.lastname: Zanazzi
authors.forename: L
authors.initials: L
authors.lastname: Moscarelli
authors.forename: R
authors.initials: R
authors.lastname: Piperno
authors.forename: L
authors.initials: L
authors.lastname: Di Maria
authors.forename: E
authors.initials: E
authors.lastname: Bertoni
authors.forename: M
authors.initials: M
authors.lastname: Salvadori
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D066027:Transplant Recipients; D000077562:Valganciclovir; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000077562:Valganciclovir; D015774:Ganciclovir; D000212:Acyclovir